Group 1 - The core viewpoint of the news is that East China Pharmaceutical's subsidiary has entered into an exclusive commercialization partnership for a new drug, Linaclotide, which is expected to enhance its product portfolio in the digestive disease sector [1] - Linaclotide, developed in collaboration with Cinclus Pharma, is a new generation potassium-competitive acid blocker (P-CAB) aimed at treating digestive system diseases [1] - The National Healthcare Security Administration has included Linaclotide for the treatment of reflux esophagitis in the 2025 National Medical Insurance Directory, which is expected to boost its market potential [1] Group 2 - East China Pharmaceutical focuses on innovation in three core therapeutic areas: oncology, endocrinology, and autoimmune diseases, enhancing its product pipeline through various strategies [2] - The company has a strong market promotion capability, leading to significant sales growth, with innovative product sales and agency service revenue reaching 1.675 billion yuan, a 62% year-on-year increase [2] - The CAR-T product, Zewokaiolun, has gained a strong market presence since its launch, with the company placing 170 effective orders with its partner, exceeding the total orders from the previous year [2]